Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 4/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15420956 | 0.92 | CHRM2 (0.53) | CHRM2CHRM1CHRM3GPR119USP2 | |
| SCHEMBL30277149 | 0.92 | CHRM2 (0.53) | CHRM2CHRM1CHRM3GPR119USP2 | |
| SCHEMBL15420957 | 0.92 | CHRM2 (0.53) | CHRM2CHRM1CHRM3GPR119USP2 | |
| Trifluoroacetic Acid SCHEMBL15546542 | 0.81 | — | — | |
| SCHEMBL13243423 | 0.79 | CHRM2 (0.59) | CHRM2CHRM1CHRM3GPR119USP2 | |
| SCHEMBL19713546 | 0.79 | CHRM2 (0.51) | CHRM2CHRM1CHRM3GPR119USP2 | |
| SCHEMBL17705982 | 0.78 | CHRM2 (0.54) | CHRM2CHRM1CHRM3GPR119USP2 | |
| SCHEMBL21314139 | 0.78 | CHRM2 (0.73) | CHRM2CHRM1CHRM3GPR119USP2 | |
| SCHEMBL21314137 | 0.78 | CHRM2 (0.73) | CHRM2CHRM1CHRM3GPR119USP2 | |
| Trifluoroacetic Acid SCHEMBL15420962 | 0.78 | HTR3A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312169-B1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-09-15 | — | — | EP | disclosed |
| US-10407443-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| EP-2875012-B1 | 5HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-10125145-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-13 | — | — | US | disclosed |
| EP-3312169-A1 | 5-HT3 RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | TAKEDA CALIFORNIA, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20170260201-A1 | 5-HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9695195-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9670229-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-06 | — | — | US | disclosed |
| US-20160251373-A1 | 5-HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2016-06-30 | — | — | US | disclosed |
| US-9346829-B2 | 5-HT3 receptor antagonists | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| US-9303045-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150182533-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-02 | — | — | US | disclosed |
| US-9012447-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-21 | — | — | US | disclosed |
| US-20140024644-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407443-B2 | 5-HT3 receptor antagonists | HTR3A, HTR3B, HTR5A | CHRM2 383/4885CHRM1 331/4885CHRM3 185/4885 |
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | CHRM2 350/4885CHRM1 338/4885CHRM3 148/4885 |
| US-20170260201-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | CHRM2 383/4885CHRM1 331/4885CHRM3 185/4885 |
| US-20150182533-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR3E | CHRM2 134/4885CHRM1 169/4885CHRM3 47/4885 |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | CHRM2 350/4885CHRM1 338/4885CHRM3 148/4885 |
| US-20140024644-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | CHRM2 383/4885CHRM1 331/4885CHRM3 185/4885 |
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | CHRM2 327/4885CHRM1 328/4885CHRM3 138/4885 |
| US-20160251373-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | CHRM2 383/4885CHRM1 331/4885CHRM3 185/4885 |
| US-10125145-B2 | 5-HT3 receptor antagonists | HTR3A, HTR3B, HTR5A | CHRM2 383/4885CHRM1 331/4885CHRM3 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.